Epilepsy and inflammation in the brain

Overview and pathophysiology

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

The possibility that inflammatory processes in the brain contribute to the etiopathogenesis of seizures and the establishment of a chronic epileptic focus is increasingly recognized as a result of supportive evidence in experimental models and in the clinical setting. Prototypical inflammatory cytokines (such as IL-1beta) and "danger signals" (such as HMGB1 and S100beta) are overexpressed in human and experimental epileptogenic tissue, prominently by glia. Neurons and endothelial cells of the blood-brain barrier contribute to inflammatory processes. All these cell types also express receptors for inflammatory mediators, suggesting that inflammatory molecules in the brain exert both autocrine and paracrine activation of intracellular signaling cascades; thus, they may act as soluble mediators of cell communication in diseased tissue. In experimental models, seizures also trigger brain inflammation in the absence of cell loss; in human epileptogenic tissue, the type of neuropathology associated with chronic seizures contributes to determine the type of cells expressing the inflammatory mediators, and the extent to which inflammation occurs. Inflammatory molecules, such as IL-1beta and HMGB1, have proconvulsant activity in various seizure models, most likely by decreasing seizure threshold via functional interactions with classical neurotransmitter systems. These findings reveal novel glioneuronal communications in epileptic tissue that highlight potential new targets for therapeutic intervention.

Original languageEnglish
Pages (from-to)3-7
Number of pages5
JournalEpilepsy Currents
Volume14
Issue numberSUPPL.1
DOIs
Publication statusPublished - 2014

Fingerprint

Encephalitis
Epilepsy
Seizures
HMGB1 Protein
Theoretical Models
Brain
Blood-Brain Barrier
Cell Communication
Neuroglia
Neurotransmitter Agents
Endothelial Cells
Communication
Cytokines
Inflammation
Neurons

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Epilepsy and inflammation in the brain : Overview and pathophysiology. / Vezzani, Annamaria.

In: Epilepsy Currents, Vol. 14, No. SUPPL.1, 2014, p. 3-7.

Research output: Contribution to journalArticle

@article{7b335908d8054710b737ec16d77cb0b8,
title = "Epilepsy and inflammation in the brain: Overview and pathophysiology",
abstract = "The possibility that inflammatory processes in the brain contribute to the etiopathogenesis of seizures and the establishment of a chronic epileptic focus is increasingly recognized as a result of supportive evidence in experimental models and in the clinical setting. Prototypical inflammatory cytokines (such as IL-1beta) and {"}danger signals{"} (such as HMGB1 and S100beta) are overexpressed in human and experimental epileptogenic tissue, prominently by glia. Neurons and endothelial cells of the blood-brain barrier contribute to inflammatory processes. All these cell types also express receptors for inflammatory mediators, suggesting that inflammatory molecules in the brain exert both autocrine and paracrine activation of intracellular signaling cascades; thus, they may act as soluble mediators of cell communication in diseased tissue. In experimental models, seizures also trigger brain inflammation in the absence of cell loss; in human epileptogenic tissue, the type of neuropathology associated with chronic seizures contributes to determine the type of cells expressing the inflammatory mediators, and the extent to which inflammation occurs. Inflammatory molecules, such as IL-1beta and HMGB1, have proconvulsant activity in various seizure models, most likely by decreasing seizure threshold via functional interactions with classical neurotransmitter systems. These findings reveal novel glioneuronal communications in epileptic tissue that highlight potential new targets for therapeutic intervention.",
author = "Annamaria Vezzani",
year = "2014",
doi = "10.5698/1535-7511-14.s2.3",
language = "English",
volume = "14",
pages = "3--7",
journal = "Epilepsy Currents",
issn = "1535-7597",
publisher = "American Epilepsy Society",
number = "SUPPL.1",

}

TY - JOUR

T1 - Epilepsy and inflammation in the brain

T2 - Overview and pathophysiology

AU - Vezzani, Annamaria

PY - 2014

Y1 - 2014

N2 - The possibility that inflammatory processes in the brain contribute to the etiopathogenesis of seizures and the establishment of a chronic epileptic focus is increasingly recognized as a result of supportive evidence in experimental models and in the clinical setting. Prototypical inflammatory cytokines (such as IL-1beta) and "danger signals" (such as HMGB1 and S100beta) are overexpressed in human and experimental epileptogenic tissue, prominently by glia. Neurons and endothelial cells of the blood-brain barrier contribute to inflammatory processes. All these cell types also express receptors for inflammatory mediators, suggesting that inflammatory molecules in the brain exert both autocrine and paracrine activation of intracellular signaling cascades; thus, they may act as soluble mediators of cell communication in diseased tissue. In experimental models, seizures also trigger brain inflammation in the absence of cell loss; in human epileptogenic tissue, the type of neuropathology associated with chronic seizures contributes to determine the type of cells expressing the inflammatory mediators, and the extent to which inflammation occurs. Inflammatory molecules, such as IL-1beta and HMGB1, have proconvulsant activity in various seizure models, most likely by decreasing seizure threshold via functional interactions with classical neurotransmitter systems. These findings reveal novel glioneuronal communications in epileptic tissue that highlight potential new targets for therapeutic intervention.

AB - The possibility that inflammatory processes in the brain contribute to the etiopathogenesis of seizures and the establishment of a chronic epileptic focus is increasingly recognized as a result of supportive evidence in experimental models and in the clinical setting. Prototypical inflammatory cytokines (such as IL-1beta) and "danger signals" (such as HMGB1 and S100beta) are overexpressed in human and experimental epileptogenic tissue, prominently by glia. Neurons and endothelial cells of the blood-brain barrier contribute to inflammatory processes. All these cell types also express receptors for inflammatory mediators, suggesting that inflammatory molecules in the brain exert both autocrine and paracrine activation of intracellular signaling cascades; thus, they may act as soluble mediators of cell communication in diseased tissue. In experimental models, seizures also trigger brain inflammation in the absence of cell loss; in human epileptogenic tissue, the type of neuropathology associated with chronic seizures contributes to determine the type of cells expressing the inflammatory mediators, and the extent to which inflammation occurs. Inflammatory molecules, such as IL-1beta and HMGB1, have proconvulsant activity in various seizure models, most likely by decreasing seizure threshold via functional interactions with classical neurotransmitter systems. These findings reveal novel glioneuronal communications in epileptic tissue that highlight potential new targets for therapeutic intervention.

UR - http://www.scopus.com/inward/record.url?scp=84897933220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897933220&partnerID=8YFLogxK

U2 - 10.5698/1535-7511-14.s2.3

DO - 10.5698/1535-7511-14.s2.3

M3 - Article

VL - 14

SP - 3

EP - 7

JO - Epilepsy Currents

JF - Epilepsy Currents

SN - 1535-7597

IS - SUPPL.1

ER -